Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK

Background: A superior survival benefit with atezolizumab (atezo; anti–PD-L1) vs docetaxel (doc; HR 0.73; 95% CI: 0.62, 0.87) has been demonstrated in OAK, the first randomized Ph III study of atezo in NSCLC patients (pts) who had failed prior platinum therapy. In the primary efficacy population (n = 850), atezo benefit was seen regardless of PD-L1 expression levels on tumor cells (TC) or tumor-infiltrating immune cells (IC). Here, we present...